SynthesisCurrent cardiology reports2018
ECMO and Short-term Support for Cardiogenic Shock in Heart Failure.
Synthesis in Current cardiology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Mechanical circulatory support devices in heart failure: a narrative review of current evidence, clinical applications, complications, and future directions.Frontiers in cardiovascular medicine · 2026Review
- Special topics: heart failure-related cardiogenic shock, valvular heart disease and end-stage renal disease. Part 4 of the International Expert Opinion Series on Acute Heart Failure Management.Heart failure reviews · 2025Review
- A Novel Valveless Pulsatile Flow Pump for Extracorporeal Blood Circulation.Annals of biomedical engineering · 2025Article
- Successful ECMO support for cardiogenic shock induced by immune checkpoint inhibitor-associated myocarditis: a case report and literature review.Frontiers in immunology · 2025Review
- Current state of heart failure treatment: are mesenchymal stem cells and their exosomes a future therapy?Frontiers in cardiovascular medicine · 2025Review
- Empirical and Computational Evaluation of Hemolysis in a Microfluidic Extracorporeal Membrane Oxygenator Prototype.Micromachines · 2024Article
- The Use of Cardioprotective Devices and Strategies in Patients Undergoing Percutaneous Procedures and Cardiac Surgery.Healthcare (Basel, Switzerland) · 2023Review
- Keep the Right in Mind-A Focused Approach to Right Ventricle-Predominant Cardiogenic Shock.Life (Basel, Switzerland) · 2023Review
- Risk stratification in cardiogenic shock: a focus on the available evidence.Heart failure reviews · 2022Review
- Long-Term Follow-Up of Survivors of Extracorporeal Life Support Therapy for Cardiogenic Shock: Are They Really Survivors?Medicina (Kaunas, Lithuania) · 2022Article
- Thyrotoxicosis-Induced Cardiomyopathy Complicated by Refractory Cardiogenic Shock Rescued by Extracorporeal Membrane Oxygenation.The American journal of case reports · 2022Article
- Observational
- Current Landscape of Temporary Percutaneous Mechanical Circulatory Support Technology.US cardiology · 2021Review
- Cardiac intensive care management of high-risk percutaneous coronary intervention using the venoarterial ECMO support.Heart failure reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review aims to discuss the role of ECMO in the treatment of cardiogenic shock in heart failure. RECENT
findingsTrials done previously have shown that IABP does not improve survival in cardiogenic shock compared to medical treatment, and that neither Impella 2.5 nor TandemHeart improves survival compared to IABP. The "IMPRESS in severe shock" trial compared Impella CP with IABP and found no difference in survival. A meta-analysis of cohort studies comparing ECMO with IABP showed 33% improved 30-day survival with ECMO (risk difference 33%; 95% CI 14-52%; p = 0.0008; NNT 3). ECMO is indicated in medically refractory cardiogenic shock. ECMO can be considered in cardiogenic shock patients with estimated mortality of more than 50%. ECMO is probably the MCS of choice in cardiogenic shock with; biventricular failure, respiratory failure, life-threatening arrhythmias and cardiac arrest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.